Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticles as Monotherapy or in Combination in Acute Myeloid Leukemia Participants.

Trial Identifier: D6130C00003
Sponsor: AstraZeneca
NCTID:: NCT03217838
Start Date: July 2017
Primary Completion Date: March 2021
Study Completion Date: March 2021
Condition: Leukemia

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations